Inhibition of SARS-CoV-2 spike S1–ACE2 binding interaction and downregulation of ACE2 gene expression by Malaysian stingless bee honey and its bioactive compound, stilbamidine (SDC)
- 25 April 2026
- journal article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infects host cells by binding to angiotensin-converting enzyme 2 (ACE2). Stilbamidine (SDC), a compound identified in Malaysian Kelulut honey (KH), has been reported to exhibit favourable binding affinity towards ACE2. This study aims to determine the effects of KH and SDC on the binding of spike protein to the ACE2 receptor, as well as to assess their modulatory potential on ACE2 gene and protein expression in lung and kidney cells. KH, SDC, and MLN 4760 (ACE2 inhibitor) were tested using an in vitro spike S1:ACE2 inhibition assay. Their modulatory effects on the ACE2 gene and protein expression were further examined through real-time PCR and western blot analysis. KH inhibited the binding of Spike S1 to ACE2, surpassing MLN4760, with maximum effects (Emax) of 82.66 ± 0.24% and 59.81 ± 8.00%, respectively, while the Emax for SDC was 19.93 ± 0.4%. KH caused a significant, dose-dependent downregulation of ACE2 gene expression in kidney-derived Vero E6 cells after 24 h of treatment, whereas SDC reduced ACE2 gene expression in lung-derived A549-ACE2-TMPRSS2 cells after 72 h. Nevertheless, ACE2 protein expression remained unchanged following both treatments. KH and SDC inhibit the binding of the SARS-CoV-2 spike S1 protein to the ACE2 receptor and reduce ACE2 gene expression. The efficacy of ACE2-targeted interventions may be limited by ACE2 polymorphisms and inter-individual expression differences. Further in vivo studies are needed to confirm their prophylactic and therapeutic potential against SARS-CoV-2 infection.Keywords
Funding Information
- Ministry of Higher Education, Malaysia (FRGS/1/2022/SKK10/UIAM/02/3)
This publication has 53 references indexed in Scilit:
- Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseasesAntiviral Research, 2025
- ACE2, a therapeutic target of COVID-19, needs to be treated with cautionArchives of Virology, 2025
- A narrative review on the physicochemical profiles, bioactive compounds, and therapeutic potentials of stingless bee honeyDiscover Food, 2025
- Effect of B12 and folate deficiency in hypomethylation of Angiotensin I converting enzyme 2 gene and severity of disease among the acute respiratory distress syndrome patientsJournal of Clinical Laboratory Analysis, 2023
- Clinical features and prognostic factors of patients with COVID-19 in Henan Province, ChinaHuman Cell, 2021
- Stingless bee honey (Hymenoptera, Apidae, Meliponini): a review of quality control, chemical profile, and biological potentialApidologie, 2021
- Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID‐19 (SARS‐CoV‐2)Phytotherapy Research, 2020
- Transcriptional noise in intact and TGF‐beta treated human kidney cells; the importance of time‐series designsCell Biology International, 2018
- ACE2, angiotensin-(1–7), and Mas: the other side of the coinPflügers Archiv - European Journal of Physiology, 2012
- Natural Products as a Foundation for Drug DiscoveryCurrent Protocols in Pharmacology, 2009